Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amiodarone: clinical trials.

G V Naccarelli1, D L Wolbrette, H M Patel

  • 1Section of Cardiology and the Cardiovascular Center, Penn State University College of Medicine, Milton S. Hershey Medical Center 17033, USA.

Current Opinion in Cardiology
|February 10, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Green approach for synthesis of bioactive Hantzsch 1,4-dihydropyridine derivatives based on thiophene moiety via multicomponent reaction.

Royal Society open science·2017
Same author

Assessment of water quality index of bore well water samples from some selected locations of South Gujarat, India.

Journal of environmental science & engineering·2015
Same author

In vivo anti-tumour activity of novel Quinazoline derivatives.

European review for medical and pharmacological sciences·2012
Same author

Dental vocational training: identifying and developing trainer expertise.

British dental journal·2007
Same author

Dental vocational training: some aspects of the selection process in the South East of England.

British dental journal·2007
Same author

Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality--results of prospective analysis for the Atherosclerosis Risk in Communities study.

Journal of internal medicine·2007
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
Same journal

Advances in artificial intelligence for the evaluation of mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Role of nutritional interventions to reduce cardiometabolic disease burden in the community.

Current opinion in cardiology·2026
See all related articles

Amiodarone effectively treats arrhythmias in heart failure and post-myocardial infarction patients. However, for high-risk individuals, implantable cardioverter-defibrillators (ICDs) offer superior survival benefits compared to amiodarone therapy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Amiodarone is a widely used antiarrhythmic drug for supraventricular and ventricular tachyarrhythmias.
  • Its efficacy and safety in primary and secondary prevention of cardiac events require comprehensive review.

Purpose of the Study:

  • To review primary and secondary prevention trials involving amiodarone.
  • To analyze the clinical implications of amiodarone use in specific patient populations.
  • To compare amiodarone's effectiveness against other therapies, including implantable cardioverter-defibrillators (ICDs).

Main Methods:

  • Review of key clinical trials: EMIAT, CAMIAT, GESICA, CHF-STAT, MADIT, CASCADE, AVID, CIDS, and CASH.
  • Analysis of amiodarone's impact on mortality, arrhythmic events, and overall survival in various cardiovascular conditions.

Related Experiment Videos

  • Comparison of amiodarone versus ICD therapy in secondary prevention of sudden cardiac death.

    • Main Results:

    • Amiodarone reduced arrhythmic mortality but not overall mortality in post-myocardial infarction patients (EMIAT, CAMIAT).
    • In heart failure, amiodarone showed neutral overall survival, with trends toward improved survival in specific subgroups (GESICA, CHF-STAT).
    • ICDs demonstrated superior survival benefits over amiodarone in high-risk patients with ventricular arrhythmias (MADIT, AVID, CIDS, CASH).

    Conclusions:

    • Amiodarone is a safe and effective antiarrhythmic option for post-myocardial infarction and heart failure patients.
    • For patients with malignant arrhythmias or high risk of sudden cardiac death, ICDs are recommended as frontline therapy.
    • The choice between amiodarone and ICDs depends on individual patient risk factors and specific clinical indications.